

PRESS RELEASE

Date 21 September 2018
Contact Investor Relations: Felix Burkhard, CFO, Galenica Group
Media Relations: Christina Hertig, Head Corporate Communications, Galenica Group
Subject Early succession planning for the Products & Brands Business sector

Early succession planning for the Head of Products & Brands Business sector: Thomas Szuran will assume the role as of 14 January 2019 and will become a member of the Galenica Group Corporate Executive Committee

As part of early succession planning, the Board of Directors of the Galenica Group has appointed Thomas Szuran as the designated Head of Products & Brands Business sector and a member of the Corporate Executive Committee. Thomas Szuran will assume his new role as of 14 January 2019.

He will replace Torvald de Coverly Veale, the current Head of Products & Brands Business sector, as a member of the Corporate Executive Committee of Galenica as of this date. However, Torvald de Coverly Veale will continue to contribute his long-term consumer healthcare expertise to Verfora. He will remain a member of the Verfora executive committee and will actively support Thomas Szuran in further developing the Verfora business.

Thomas Szuran (51) was CEO of Biomed Ltd. for the last seven years and has been President of the Association of the Swiss Self-Medication Industry (ASSGP) since 2013. He has extensive experience in the pharma sector and in-depth knowledge of the Swiss healthcare market as well as international markets thanks to his working experience abroad. He brings broad OTC expertise to the Galenica Group in the areas of marketing and sales, as well as medical & regulatory affairs, making him an excellent addition to the Corporate Executive Committee. In addition to his many years of management experience, Thomas Szuran has the expertise and skills needed to drive forward the strategy of the Products & Brands Business sector and to further develop the business.

Torvald de Coverly Veale will continue to actively support Verfora

Torvald de Coverly Veale (58) joined the Galenica Group in 2015 as Head of Products & Brands Business sector, which was created at that time, bringing his 35 years of international consumer business experience to the Group. He was appointed a member of the Corporate Executive Committee at the time of the Galenica IPO in April 2017 and has since successfully continued to expand the business. The Board of Directors would like to thank Torvald de Coverly Veale for his commitment and willingness to anticipate the succession planning with this management change and to continue to contribute his know-how and experience to Verfora.

For further information, please contact:

Christina Hertig, Head Corporate Communications
Tel. +41 58 852 85 17
E-mail: media@galenica.com

Felix Burkhard, CFO
Tel. +41 58 852 85 29
E-mail: investors@galenica.com

Date 21 September 2018
Page 2/2
Subject Early succession planning for the Products & Brands Business sector

Curriculum Vitae Thomas Szuran

Dr. Thomas F. Szuran (born 1967, Federal Diploma in Natural Sciences from the Federal Institute of Technology) studied biochemistry and behavioural biology at the Federal Institute of Technology, Zurich (ETHZ) and has worked for various pharmaceutical companies in Switzerland and abroad. He started his career at Abbott Laboratories, initially in Switzerland before assuming responsibility as Sales and Marketing Manager for the Eastern Europe and Mediterranean region. In 2002, he moved to Pfizer, where he worked for three years as Sales Director in Switzerland and then as Country Manager in Israel. He returned to Switzerland in 2008 to take on the role of Marketing Director at Biomed Ltd, where he became CEO in 2011. Since 2013, he has also been President of the Association of the Swiss Self-Medication Industry (ASSGP).

Galenica is the leading fully integrated healthcare provider in Switzerland. With 500 own, joint venture and independent partner pharmacies, Galenica operates the largest network of pharmacies in Switzerland. In addition, Galenica further develops and offers well-known own brands and products, exclusive brands and products from business partners as well as a variety of on-site health services and tests for customers. Galenica is also the leading provider of prewholesale and wholesale services as well as database services in the Swiss healthcare market. Galenica is listed on the Swiss Stock Exchange (SIX Swiss Exchange, GALE, security number 36,067,446).

Additional information concerning Galenica can be found at www.galenica.com